59.01

0.20% -0.12

Exelixis Inc (EXEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EXEL? Forum Prognose

Schlusskurs vom Vortag:

$59.13

Offen:

$58.502

24-Stunden-Volumen:

1.58M

Relative Volume:

0.61

Marktkapitalisierung:

$14.62B

Einnahmen:

$2.38B

Nettoeinkommen (Verlust:

$833.42M

KGV:

19.56

EPS:

3.0172

Netto-Cashflow:

$917.69M

1W Leistung:

+8.37%

1M Leistung:

+5.37%

6M Leistung:

+41.54%

1J Leistung:

+57.87%

1-Tages-Spanne:

$58.45

$59.26

1-Wochen-Bereich:

$53.43

$59.72

52-Wochen-Spanne:

$33.76

$59.72

Exelixis Inc Stock (EXEL) Company Profile

Firmenname

Exelixis Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(650) 837-7000

Adresse

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Mitarbeiter

1,077

Twitter

@exelixisinc

Nächster Verdiensttermin

2026-08-05

Neueste SEC-Einreichungen

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXEL Exelixis Inc	59.01	13.30B	2.38B	833.42M	917.69M	3.0172
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-11-03	Herabstufung	Guggenheim	Buy → Neutral
2025-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-09-19	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Eingeleitet	Goldman	Buy
2025-07-08	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Hochstufung	Stephens	Equal-Weight → Overweight
2025-02-24	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-01-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Herabstufung	BofA Securities	Buy → Neutral
2024-10-16	Bestätigt	RBC Capital Mkts	Outperform
2024-09-19	Eingeleitet	UBS	Neutral
2024-04-11	Herabstufung	Barclays	Overweight → Equal Weight
2023-12-19	Eingeleitet	BTIG Research	Buy
2023-12-15	Eingeleitet	Citigroup	Buy
2023-09-26	Eingeleitet	H.C. Wainwright	Buy
2023-08-22	Bestätigt	Oppenheimer	Outperform
2023-08-08	Eingeleitet	SVB Securities	Market Perform
2023-07-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-10	Fortgesetzt	Piper Sandler	Overweight
2023-03-09	Eingeleitet	Wells Fargo	Overweight
2023-01-26	Eingeleitet	Credit Suisse	Outperform
2022-10-18	Eingeleitet	JMP Securities	Mkt Outperform
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-11-03	Fortgesetzt	Jefferies	Buy
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Bestätigt	H.C. Wainwright	Buy
2021-06-15	Eingeleitet	H.C. Wainwright	Buy
2021-05-18	Fortgesetzt	Goldman	Sell
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-03-12	Eingeleitet	Wolfe Research	Outperform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Eingeleitet	SunTrust	Buy
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-03-18	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Eingeleitet	Goldman	Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Underweight
2018-05-11	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	RBC Capital Mkts	Outperform
2017-10-16	Bestätigt	SunTrust	Buy
2017-09-22	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-12	Bestätigt	Needham	Buy
2017-07-14	Eingeleitet	SunTrust	Buy
2017-03-31	Eingeleitet	Needham	Buy
2017-03-16	Eingeleitet	Oppenheimer	Perform
2017-02-28	Herabstufung	Stifel	Buy → Hold
2016-11-03	Eingeleitet	Deutsche Bank	Buy
2016-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-09-15	Bestätigt	Stifel	Buy

Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

Aug 21, 2026

NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL - MarketBeat

Aug 21, 2026

51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC - MarketBeat

Aug 21, 2026

BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL - MarketBeat

Aug 21, 2026

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law - The Daily Tribune News

Aug 21, 2026

Aug 20, 2026

FARALLON CAPITAL MANAGEMENT, L.L.C. Buys More Exelixis Inc (EXEL - GuruFocus

Aug 20, 2026

BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" - MarketBeat

Aug 20, 2026

Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXEL - MarketBeat

Aug 20, 2026

Out of sight, out of work? What’s driving remote job cuts - BioSpace

Aug 20, 2026

Aug 19, 2026

Investigation launched into EXELIXIS officers f... - Pluang

Aug 19, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - PR Newswire

Aug 19, 2026

Exelixis Inc : BMO Initiates Coverage With Ma - Moomoo

Aug 19, 2026

EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54 - Bitget

Aug 19, 2026

BMO initiates Exelixis stock at Market Perform, cites patent cliff By Investing.com - Investing.com Australia

Aug 19, 2026

EXEL Initiates Coverage On BMO Capital -- Price Target Announced at $54.00 - GuruFocus

Aug 19, 2026

BMO initiates Exelixis stock at Market Perform, cites patent cliff - Investing.com

Aug 19, 2026

JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL - MarketBeat

Aug 19, 2026